Constipation Predominant Irritable Bowel Syndrome Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of RDX5791 for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
This is a multi-center, Phase 2, randomized, double-blind, placebo controlled study of
RDX5791 in subjects with IBS-C. Patients who are 18 to 75 years old, meeting the definition
of IBS-C as defined by the Rome III Criteria for the Diagnosis of IBS will undergo a battery
of screening procedures to determine eligibility for the trial.
The study will consist of a 2-week treatment-free screening period, a 4-week blinded
treatment period, and a 2-week treatment-free follow-up period.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02621892 -
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
|
Phase 3 | |
| Completed |
NCT02727751 -
A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C
|
Phase 3 | |
| Completed |
NCT02686138 -
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
|
Phase 3 | |
| Completed |
NCT01923428 -
The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)
|
Phase 2/Phase 3 |